Graph AI Secures $3 Million Seed Funding to Revolutionize Pharmacovigilance with AI-Driven Safety Solutions

California-based Graph AI, a company specializing in patient safety and pharmacovigilance, has raised $3 million in Seed funding, led by Bessemer Venture Partners. The fresh capital will fuel the company’s efforts to accelerate product innovation, expand its engineering team, and drive global market adoption.

Founded in 2024, Graph AI is led by Raghav Parvataraju (CEO), Vijay Ponukumati (CTO), Mohan Konyala (CPO), and Ashutosh Bordekar (CFO) — a leadership team of industry veterans with extensive experience from global technology leaders including Infosys, Google, and ServiceNow.

Graph AI represents a new generation of AI-native innovators transforming the $8 billion pharmacovigilance industry, which plays a critical role in global healthcare. Pharmacovigilance, mandated by drug regulatory authorities worldwide, requires continuous monitoring, detection, and reporting of adverse drug events (ADEs) throughout a product’s lifecycle.

Traditionally, pharmaceutical companies outsource this process to service firms that rely heavily on manual data extraction and reporting. Graph AI disrupts this model by keeping humans-in-the-loop only for essential regulatory tasks, enabling pharma companies to transition from manual and error-prone systems to AI-powered, automated workflows. This approach enhances the efficiency, accuracy, and compliance of medical safety reviews.

In just over a year, Graph AI has achieved strong traction among enterprise clients, building a rapidly expanding pipeline covering over 7,000 drugs. Customers have reported up to 70% efficiency gains, 90% faster regulatory reporting, and significant cost reductions, all while maintaining full traceability and audit readiness.

The founders shared their vision for transforming life sciences safety systems:

“The life sciences industry continues to grapple with outdated technology, fragmented point solutions, data silos, and manual handoffs that hinder decision-making and elevate compliance risks. At Graph, we’re addressing these challenges with a unified, AI-native safety platform that integrates context, compliance, and intelligence into a single seamless ecosystem. Our vision is to make patient safety smarter, faster, and more connected, empowering pharmaceutical enterprises to achieve safer outcomes, stronger regulatory confidence, and exponential efficiency across safety operations.”

Expressing confidence in Graph AI’s potential, Nithin Kaimal, Partner at Bessemer Venture Partners India, said:

“We’re excited to partner with Graph AI as they redefine labour intensive and inefficient pharmacovigilance workflows through AI-native solutions that prioritize accuracy and scalability. At Bessemer, we’re deeply optimistic about the transformative potential of AI to reimagine traditional services models as for the first time, delivery is shifting from labour arbitrage to intelligence arbitrage, empowering enterprises to work with firms that deliver faster, smarter, and more adaptive solutions. We look forward to supporting the Graph team as they continue to scale new heights.”

With this funding, Graph AI is poised to lead the next wave of transformation in pharmacovigilance and patient safety, leveraging artificial intelligence to make safety operations more intelligent, connected, and compliant for the global life sciences ecosystem.

Also Read